e.valuation, preclinical: optimize investment
Concluding on which biomarker, target or drug lead to prioritize in preclinical development involves a cost- and time intensive R&D process, and implicitly determines the fate of assets in later clinical testing. Frequently there is not a shortage of candidates, but the critical question reads as: "what is the most promising" with respect to intended use. Such decision needs to factor in the full preclinical data space covering phenotype model results on efficacy and tox.
e.valuation application scenarios in preclinical stage asset development include:
- rank fit-for-purpose of given biomarker, target or drug leads
- determine match of preclinical model results with human disease pathophysiology
- decrease R&D costs
e.valuation provides dedicated workflows for a fit-for-purpose analysis of preclinical stage biomarker, target and drug leads, but also fosters an integrated view: drug Mechanism of Action, specific pathophysiologies and biomarker candidates: the core of precision medicine.